Related Experiment Videos
Is debrisoquine hydroxylation modified during acute viral hepatitis?
C Joanne1, G Paintaud, S Bresson-Hadni
1Department of Clinical Pharmacology, CHU Jean Minjoz, Besançon, France.
Fundamental & Clinical Pharmacology
|January 1, 1994
Summary
Acute viral hepatitis minimally impacts the activity of cytochrome P450 2D6 (CYP2D6). Patients with hepatitis can generally receive medications metabolized by CYP2D6 at standard doses.
Area of Science:
- Pharmacology
- Hepatology
- Drug Metabolism
Background:
- Liver diseases can impair drug metabolism, but specific cytochrome P450 isozyme function is often unclear.
- Understanding the impact of liver disease on drug metabolism is crucial for safe and effective pharmacotherapy.
Purpose of the Study:
- To investigate the effect of acute viral hepatitis on the activity of the CYP2D6 enzyme.
- To determine if patients with acute viral hepatitis require dosage adjustments for CYP2D6 substrates.
Main Methods:
- Studied debrisoquine hydroxylation capacity in 17 patients with acute viral hepatitis.
- Compared results with 106 healthy subjects to assess CYP2D6 metabolic ratio and phenotype prevalence.
Main Results:
- Debrisoquine metabolic ratio was significantly increased in extensive metabolizers (EMs) with acute viral hepatitis compared to healthy EMs.
- No significant difference in CYP2D6 phenotype prevalence was observed between patients and controls.
Conclusions:
- Acute viral hepatitis has a marginal effect on CYP2D6 activity.
- Substrates of CYP2D6 can likely be administered at normal therapeutic doses in patients with acute viral hepatitis.